<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220222054091N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-07</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>The effectiveness of a text message intervention on obesity in women with polycystic ovarian syndrome</public_title>
      <acronym></acronym>
      <scientific_title>The effectiveness of a text message intervention on obesity-related parameters in obese or overweight women with polycystic ovarian syndrome: a randomized controlled clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-26</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>124</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62096</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: The participants are assigned to the intervention and control groups by block randomization with a block size of 4 and 6 and with 1:1 allocation. For Allocation Concealment, the group name will be written on paper and placed inside numbered opaque envelopes. The envelopes will be opened in the order of participants entering the study and the group of participants will be determined. The randomization and preparation of envelopes will be done by someone who is not involved in sampling and data collection.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: obesity or overweight. Condition 2: polycystic ovary syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Educational brochures at the begining of study and educational text messages about the importance of weight loss on the clinical symptoms of polycystic ovary syndrome, recommendations about healthier food choices and physical activity.                                              The brochures are provided to all participants at the beginning of the study and include general information about polycystic ovary syndrome and the importance of weight loss in this disease. text messages are sent twice a week for 6 months to the study group, and participants will be asked to pay attention to these texts, read and follow them if possible.  The content of the messages will be written using scientific papers, physical activity and healthy diet guidelines published by the World Health Organization and other standard sources. The content of the messages will be reviewed and approved by specialists in nutrition, sports medicine, gynecologist, social physician and psychologist. Intervention 2: Control group: Educational brochures about the importance of weight loss on the clinical symptoms of polycystic ovary syndrome, recommendations about healthier food choices and physical activity. The brochures are provided to all participants at the beginning of the study and include general information about polycystic ovary syndrome and the importance of weight loss in this disease.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after making individuals unidentifiable

When:
Access period starts 6 months after the results are published

To whom:
Researchers working in academic and scientific institutions

Conditions:
By observing the principle of intellectual property and without making any changes or misapplication

Where to obtain:
Scientific respondent to the study E-mail :alizadm@yahoo.com Dr. Mahasti Alizadeh mizani

How to obtain:
Will be answered in less than two weeks

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>mahasti alizadeh mizani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>2nd Floor, Social Determinants of Health Research Center, Central Library of Tabriz University of Medical Sciences, University of Tabriz Campus, Daneshgah St., Tabriz, Iran</address>
        <city>tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614766</zip>
        <telephone>+98 41 3177 2334</telephone>
        <email>alizadm@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>mahasti alizadeh mizani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>2nd Floor, Social Determinants of Health Research Center, Central Library of Tabriz University of Medical Sciences, University of Tabriz Campus, Daneshgah St., Tabriz, Iran</address>
        <city>tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614766</zip>
        <telephone>+98 41 3177 2334</telephone>
        <email>alizadm@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>women with polycystic ovarian syndrome
BMI more than 25
fertility age
a desire to lose weight</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Not having a mobile phone
Use of weight loss medication
Having other metabolic diseases such as diabetes or thyroid disorders</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E66</hc_code>
      <hc_code>E28.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Overweight and obesity</hc_keyword>
      <hc_keyword>Polycystic ovarian syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Educational brochures at the begining of study and educational text messages about the importance of weight loss on the clinical symptoms of polycystic ovary syndrome, recommendations about healthier food choices and physical activity.                                              The brochures are provided to all participants at the beginning of the study and include general information about polycystic ovary syndrome and the importance of weight loss in this disease. text messages are sent twice a week for 6 months to the study group, and participants will be asked to pay attention to these texts, read and follow them if possible.  The content of the messages will be written using scientific papers, physical activity and healthy diet guidelines published by the World Health Organization and other standard sources. The content of the messages will be reviewed and approved by specialists in nutrition, sports medicine, gynecologist, social physician and psychologist.</i_keyword>
      <i_keyword>Control group: Educational brochures about the importance of weight loss on the clinical symptoms of polycystic ovary syndrome, recommendations about healthier food choices and physical activity. The brochures are provided to all participants at the beginning of the study and include general information about polycystic ovary syndrome and the importance of weight loss in this disease.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Body weight. Timepoint: At the beginning of the study, after 3 months and 6 months of intervention. Method of measurement: Weighing scale.</prim_outcome>
      <prim_outcome>Waist circumference. Timepoint: At the beginning of the study, after 3 months and 6 months of intervention. Method of measurement: tape measure.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Average physical activity. Timepoint: At the beginning of the study, after 3 months and 6 months of intervention. Method of measurement: International Physical Activity Questionnaire.</sec_outcome>
      <sec_outcome>Diet. Timepoint: At the beginning of the study, after 3 months and 6 months of intervention. Method of measurement: 3-day food records questionnaire.</sec_outcome>
      <sec_outcome>Appetite. Timepoint: At the beginning of the study, after 3 months and 6 months of intervention. Method of measurement: appetite questionnaire.</sec_outcome>
      <sec_outcome>Hip circumference. Timepoint: At the beginning of the study, after 3 months and 6 months of intervention. Method of measurement: tape measure.</sec_outcome>
      <sec_outcome>Body mass index. Timepoint: At the beginning of the study, after 3 months and 6 months of intervention. Method of measurement: weight in kilograms divided by height in meters squared.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-10-31</approval_date>
        <contact_name>Ethics Committee Of Tabriz University Of Medical Sciences</contact_name>
        <contact_address>Third Floor, Central Building Number 2, Golgasht Street tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
